Market Overview

The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows

The Daily Biotech Pulse: Merck's Keytruda Secures Approval For Expanded Label, ProPhase Labs Q2 Loss Narrows
Related IBB
The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs
The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise
Related MRK
4 Major Market Opportunities For The Cannabis Industry
The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program
Merck's Keytruda + Pfizer's Inlyta successful in late-stage kidney cancer study (Seeking Alpha)

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 20)

  • Avanos Medical Inc (NYSE: AVNS)
  • Becton Dickinson and Co (NYSE: BDX)
  • DexCom, Inc. (NASDAQ: DXCM)
  • Eli Lilly And Co (NYSE: LLY)
  • Liquidia Technologies Inc (NASDAQ: LQDA)
  • Masimo Corporation (NASDAQ: MASI)
  • Merck & Co., Inc. (NYSE: MRK)
  • Neogen Corporation (NASDAQ: NEOG)
  • Pfizer Inc. (NYSE: PFE)
  • Tandem Diabetes Care Inc (NASDAQ: TNDM)

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 20)

  • Alpine Immune Sciences Inc (NASDAQ: ALPN)
  • Aralez Pharmaceuticals Inc (NASDAQ: ARLZ)
  • Avadel Pharmaceuticals PLC (ADR) (NASDAQ: AVDL)
  • Cesca Therapeutics Inc (NASDAQ: KOOL)
  • Dynavax Technologies Corporation (NASDAQ: DVAX)
  • Exelixis, Inc. (NASDAQ: EXEL)
  • Novan Inc (NASDAQ: NOVN) )(reported positive results for its SB414 in two complementary Phase 1b clinical trials)
  • Sellas Life Sciences Group Inc (NASDAQ: SLS)
  • Surface Oncology Inc (NASDAQ: SURF)
  • Sinovac Biotech Ltd. (NASDAQ: SVA)(announced conclusion of SEC investigation on allegations of some employees making improper payments to Chinese government officials)
  • Trinity Biotech plc (ADR) (NASDAQ: TRIB)

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs

Stocks In Focus

FDA Approves Expanded Label For Merck's Keytruda

Merck announced the FDA has approved an expanded label for its Keytruda, with the drug in combination with pemetrexed and platinum chemotherapy now being approved as a first-line treatment for patients with metastatic non-squamous non-small cell lung cancer, with no EGFR or ALK genomic tumor aberrations.

The company said the approval was based on data from the KEYNOTE-189 trial.

ProPhase Labs Q2 Loss Narrows

ProPhase Labs Inc (NASDAQ: PRPH) reported a second-quarter net sales from continuing operations of $3.2 million compared to $1.9 million in the year-ago period. The company's net loss narrowed from 14 cents per share in Q217 to 2 cents per share in Q218.

On The Radar


Medtronic PLC (NYSE: MDT) Q1 Adj. EPS $1.17 Beats $1.11 Estimate, Sales $7.4B Beat $7.24B Estimate
Myriad Genetics, Inc. (NASDAQ: MYGN) (after the close)

Posted-In: Biotech Earnings News FDA Top Stories Trading Ideas Best of Benzinga


Related Articles (ALPN + ARLZ)

View Comments and Join the Discussion!

Madison Square Garden Trading At Discount To Intrinsic Value, Imperial Capital Says In Bullish Initiation

25 Stocks Moving In Tuesday's Pre-Market Session